Inmed Pharmaceuticals Inc's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Inmed Pharmaceuticals Inc's ROA in the fourth quarter of 2026?
Inmed Pharmaceuticals Inc recorded a cumulative net loss of $-13 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -72.57%.

However, within the Healthcare sector 866 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2026 from 4329 to 4425.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	-23.08 %	-13.09 %	61.9 %	27.38 %	15.66 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	-9	-8	-8	-8
Return On Assets (TTM)	-72.57 %	-41.66 %	-36.9 %	-42.59 %	-43.97 %
INM's Total Ranking	# 4425	# 4329	# 4508	# 4853	# 4373
Total Assets (TTM) in million	34	9	16	13	44
Seq. Total Assets Change	270.82 %	-41.78 %	16.88 %	-69.52 %	318.99 %
Seq. Net Income Change	-	-	-	-	-

INM's 5 Years Annual ROA >> Back to INM Management Effectiveness >> Compare INM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 413
Sector	# 867
Overall	# 4610

Return On Assets Statistics
High	Average	Low
58.96 %	-60.3 %	-134.34 %
(Jun 30 2021)		(Jun 30 2022)

Financial Statements
Inmed Pharmaceuticals Inc's Assets	$ 34 million	INM's Balance sheet
Inmed Pharmaceuticals Inc's Income	$ -6 million	Quarterly INM's Income Statement
INM's Income by Division		See INM's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Mar 31 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	-23.08 %	227.34 %	-5.3 %	10.31 %	30.74 %
Total Assets in million	34	44	13	14	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	-8	-2	-8	-19
Annual Return On Assets	-37.34 %	-18.67 %	-12.9 %	-56.34 %	-145.45 %

INM's 5 Years Annual ROA >> Back to INM Management Effectiveness >> Compare INM ROA to its Competitors

More Return On Assets Ratios
INM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INM's Competitors
Subscribers only: Roa for Inmed Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for INM's Customers

You may also want to know
INM's Roi	INM's Inventory Turnover Ratio	INM's Growth Rates	INM's Dividend Comparisons
	INM's Profitability Ratios	INM's Asset Turnover Ratio	INM's Dividend Growth
INM's Roe	INM's Valuation Ratios	INM's Financial Strength Ratios	INM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T13:47:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.